Seller record · orderlymeds.com

OrderlyMeds

Recorded September 2026 · Standard v1.1

Fails 1 of 8 criteria. S5, analytical documentation: The site asserts batch testing for sterility and potency, and no certificate of analysis, chromatogram or lot document is reachable from any page read.

Telehealth service. Passes 7 of 8 criteria. Recorded against Standard v1.1.

A Georgia telehealth platform selling compounded semaglutide and tirzepatide alongside brand products. Its pages name several different sets of filling pharmacies, and an FDA warning letter names the operating entity.

Operating entity OrderlyMeds LLC

Dispositions

Code	Criterion	Disposition	Where it was read
S1	Prescriber requirement	PASS	orderlymeds.com
S2	Prescription gating	PASS	patients.orderlymeds.com/eligibility
S3	Pharmacy identification	PASS	orderlymeds.com/faqs
S4	Compounding disclosure	PASS	orderlymeds.com/treatments/glp1s/compounded-glp1
S5	Analytical documentation	FAIL	orderlymeds.com
S6	Business address	PASS	orderlymeds.com/terms-conditions
S7	Price disclosure	PASS	orderlymeds.com/pricing
S8	Enforcement status	PASS	FDA warning-letter index

Evidence, criterion by criterion

What was read, where, and on what date, for each disposition in the table above.

S1PASSThe homepage states that a licensed physician reviews the health screening and holds a video visit where the state requires one, and a named Chief Medical Officer has a profile page.Source: orderlymeds.com.

S2PASSThe order path was walked and stopped at an account-creation screen demanding a name, an email address and a telephone number, after an eligibility verdict.Source: patients.orderlymeds.com/eligibility.

S3PASSThe frequently asked questions page names five filling pharmacies, PerfectRx/PerfectionRx, ProRx, Casa, Pharmacy Hub and SmartPharmaRx, with no address or state for any; other pages name different sets.Source: orderlymeds.com/faqs.

S4PASSThe compounded product page carries the words compounded and not FDA-approved in visible text below the price block, repeated in the homepage price footnote.Source: orderlymeds.com/treatments/glp1s/compounded-glp1.

S5FAILThe site asserts batch testing for sterility and potency, and no certificate of analysis, chromatogram or lot document is reachable from any page read.Source: orderlymeds.com.

S6PASSThe terms print a street address with a suite number and describe it as the company offices, repeated in the privacy policy.Source: orderlymeds.com/terms-conditions.

S7PASSThe pricing page prints 149 dollars per month for compounded GLP-1 injections and 299 dollars per month for compounded GLP-1 plus GIP, with brand plans at 1,839 dollars and 1,498 dollars.Source: orderlymeds.com/pricing.

S8PASSFDA warning letter 728291, June 2026, names OrderlyMeds LLC and alleges misbranding; no FDA action has halted the business, and the seller still trades.Source: FDA warning-letter index.

Products shown on the seller's own pages at the recorded date: compounded semaglutide, compounded tirzepatide, Wegovy, Zepbound, NAD+, sermorelin.

Enforcement documents on file: 1 warning letter

FDA warning letter 728291, issued June 2026, to OrderlyMeds LLC dba OrderlyMedsA pictured label carries the OrderlyMeds logo, suggesting it is the compounder when it is not, and the site described its source as an FDA-licensed pharmacy, a designation FDA does not grant.

A warning letter alleges violations and requests a response. It does not halt a business, and it does not remove a seller from this ledger. Every letter recorded here.

Dispositions recorded against Standard v1.1. Method and null semantics: how checks are performed. This record is not a review and contains no medical advice.